WCG, a provider of clinical trial solutions, has acquired another Princeton company, a life sciences consulting firm, it announced Tuesday.
The deal for the Avoca Group will expand WCG’s portfolio of solutions for reducing time and expenses of clinical trials, including fortifying its benchmarking and analytics and more.
“We are delighted to welcome the Avoca Group to WCG,” Chairman and CEO Donald A. Deieso said in a prepared statement. “… The Avoca Group brings exceptionally strong leadership to WCG and the respect and engagement of top-tier biopharmaceutical companies, (contract research organizations) and clinical research sites in their work of establishing clinical trial best practices. The combination of the Avoca Group and WCG will provide the energy needed to drive quality management transformation throughout the industry.”
The Avoca Group will be renamed WCG Avoca and retain both its leadership structure and Princeton headquarters.
“We’re excited to join the WCG family and to build on the 20-plus years of experience in challenging and driving change in the clinical trial execution process,” Patricia Leuchten, founder and CEO of the Avoca Group, said in a statement. “Our mission aligns with the mission of WCG as a transformative and unifying force for increasing the quality and compliance of clinical trials, assuring that medicines can reach patients faster and reliably.”